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T
he global obesity epidemic affects billions of
people (1), and, in its wake, a worldwide epi-
demic of type 2 diabetes has followed (2,3).
Obesity is not only associated with diabetes, of
course, but also with the other partners in the X-gang:
hypertension, hyperlipidemia, and cardiovascular disease
(4). As exempliﬁed in an original article in this issue of
Diabetes (5), the link between diabetes and obesity con-
tinues to be scrutinized in detail. In the wake of this
metabolic catastrophe, the ill effects of joint pain, degen-
erative arthritis, and sleep apnea ensue (6). A ripple of
despair similarly washes over the oncology community,
who now realize that the global tragedy of obesity claims
cancer lives too (7–10). “But how about us?” the immunol-
ogists (11) and vascular (4) specialists cry; obesity dulls
the body’s response to infection, impairs wound healing,
and, consequently, diminishes reproductive capacity (12).
All of this is important, but none of it matters to Keith
Mitchell, who expresses his frustration to his impotent
physician, “Doc, I’ve tried every diet on earth. Why can’t
you help me?” (13). Keith returns home bereft of hope to
later apologize to his children, with whom he is too tired to
play (14), and to his wife, whom he feels ill adept to love.
Obesity touches every aspect of society, from the eco-
nomic viability of nations (15) to the look of defeat
reﬂected in the eyes of Keith’s daughter as she gazes upon
her broken father (16). The obesity epidemic accounted
for 27% of the increase in health care spending in the U.S.
between 1987 and 2001 (17). Is it any surprise that we in
the medical community feel despair at our incapacity to
provide scalable real-world solutions to the 300 trillion
excess calories stored in the human fuel reserve and its
associated torrent of disease? (An average person with a
BMI of 22 kg/m
2 has 13 kg of fat mass, and an average
person with a BMI of 33 kg/m
2 has 36 kg of fat mass. The
difference is 20,000 g or 180,000 kcal. With 1.5 billion
[1,500,000,000] people in the world with obesity, the
excess stored calories approximate 270,000,000,000,000
kcal.)
The notion of a polypill to prevent X-gang disease has
been touted for a decade (18–24). The most popular
variant of this concept is a tablet that people take as early
as childhood to prevent the onset of metabolic diseases
and even obesity itself. If such a tablet were available,
clinically effective, safe, and affordable, we would run out
of ink (or toner cartridges) prescribing it. Prescribing such
a polypill would become the mandate of thousands of
health care professionals worldwide. We would all sleep
better at night, knowing that Keith was.
What would be the mode of action of such a polypill? A
polypill might function via several pathways such as
through molecular targets (e.g., the insulin/insulin-recep-
tor pathways) (25), on speciﬁc tissues such as muscle and
adipose (26), and/or through neuronal (26) and humeral
effectors (27). Because the discovery path for a single pill
with such broad-ranging targets is prolonged and exhaus-
tive (28), a polypill that contains multiple, preexisting
chemicals is a more logical approach for preventing met-
abolic disease and obesity.
The problem with a broadly functioning, chemically
complex polypill is that side effects and multiple interac-
tions with other medications are likely to result once
global deployment has been achieved. However, like
crossing the road, we must consider the beneﬁt-to-risk
ratio. Understanding that more than 5% of the U.S. popu-
lation has diabetes and, for the ﬁrst time in history, at least
one or two of Keith’s daughter’s friends will develop type
2 diabetes (2,3), what safety proﬁle should we tolerate? A
few deaths sacriﬁced for the salvation of the many is the
burden long born by federal agencies such as the Food and
Drug Administration (29).
With the magnitude of obesity-associated health prob-
lems and the impact of obesity on health care costs, cogent
arguments for urgent implementation of an effective polyp-
ill are easy proffered. It is therefore with delight, at the
dawn of a new year, that we are able to announce the
release to market of an effective Pol-e-pill. The Pol-e-pill,
discovered two centuries ago (30), has been independently
tested at multiple centers across the world and has been
the focus of numerous publications and government re-
ports (31–37). The Pol-e-pill’s mode of action affects
multiple molecular targets and it is efﬁcacious at squelch-
ing the gang of four (diabetes, hypertension, hyperlipid-
emia, and cardiovascular disease) (38–41), positively
affecting multiple other obesity-associated comorbidities
and, when prescribed at a high enough dose, decreasing
body weight (35,42–45).
The Pol-e-pill has an excellent dose-response curve (46)
and a superb safety proﬁle. At low doses, the Pol-e-pill is
essentially free of side effects (although in the unwell, the
low-dose Pol-e-pill needs to be carefully monitored). How-
ever, at supra-optimal doses, the Pol-e-pill does have an
increased incidence of adverse effects, which can be
ameliorated by decreasing the dose (47). Better still, the
Pol-e-pill is not constrained through any active patents,
and so its cost is low. The Pol-e-pill can be potentially
prescribed across the world today.
So, it is ﬁnally here—Keith’s dream—an effective “pre-
scribe-able ” solution for preventing and treating diabetes,
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dose-response effects, safety proﬁle, and low cost render
the Pol-e-pill amenable to worldwide prescription. Check
the cartridge in your Pharma-labeled pen and the toner
level in your printer—Keith is on his way.
The Pol-e-pill is exercise. Prescribe it. The package
insert, with details on indications and contraindications,
beneﬁts and risks, dosage and administration, supporting
evidence, and additional resources for clinicians and pa-
tients, is available at http://exerciseismedicine.org/. We
urge physicians to prescribe exercise just as they would a
more costly tablet.
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